• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Fight Aging! Newsletter, May 2nd 2016
This study is the first CAR T-cell trial to infuse patients with an even mixture of two types of T cells (helper and killer cells, which work together to kill cancer). With the assurance that each patient gets the same mixture of cells, the researchers were able to come to conclusions about the effects of administering different doses of cells. In 27 of 29 participants whose responses were evaluated a few weeks after the infusion, a high-sensitivity test could detect no trace of their cancer in their bone marrow. The CAR T cells eliminated cancers anywhere in the body they appeared. Of the two participants who did n...
Source: Fight Aging! - May 1, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

NIH and Other Public Private Partnerships to Research Treatments for Multiple Diseases
Over the past few weeks, the National Institutes of Health (NIH) has made a number of important announcements regarding collaborations with industry as well as the funding of several new research initiatives. Below is a summary of these stories. NIH Partners With Eli Lilly and Others on Rare Diseases FierceBiotechResearch reported that NIH selected four (4) new preclinical drug development studies to uncover new therapies for rare diseases. The projects will be funded through the Therapeutics for Rare and Neglected Diseases (TRND) program under NIH's National Center for Advancing Translational Sciences, NCATS, which ...
Source: Policy and Medicine - October 4, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs